Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
Status:
Not yet recruiting
Trial end date:
2031-01-01
Target enrollment:
Participant gender:
Summary
The RAINBO umbrella program consists of four clinical trials investigating new adjuvant
therapies in endometrial cancer patients. Eligible patients will be assigned to one of the
four RAINBO trials based on the molecular profile of their cancer:
- p53 abnormal endometrial cancer patients to the p53abn-RED trial
- mismatch repair deficient endometrial cancer patients to the MMRd-GREEN trial
- no specific molecular profile endometrial cancer patients to NSMP-ORANGE trial
- POLE mutant endometrial cancer patients to the POLEmut-BLUE trial
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Leiden University Medical Center
Collaborators:
AstraZeneca Canadian Cancer Trials Group Comprehensive Cancer Centre The Netherlands Dutch Cancer Society Dutch Gynaecological Oncology Group Gustave Roussy, Cancer Campus, Grand Paris Institute of Cancer Research, United Kingdom